David A. Siegel 2seventy Bio, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 15,200 shares of TSVT stock, worth $54,872. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,200
Previous 16,000
5.0%
Holding current value
$54,872
Previous $61,000
16.39%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TSVT
# of Institutions
126Shares Held
45.6MCall Options Held
122KPut Options Held
19.8K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$21.5 Million2.31% of portfolio
-
Goldman Sachs Group Inc New York, NY4.22MShares$15.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.77MShares$13.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$13.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.89MShares$10.4 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $137M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...